Q-omics provides the consensus-scored TMEM126A profile across patient tissues and cancer cell-line models. TMEM126A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, TMEM126A is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, TMEM126A RNA expression shows 17,905 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, KIRC, and UVM as cancer lineages where TMEM126A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM126A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM126A survival associations across molecular data types. TMEM126A RNA expression shows survival associations in the most cancer types (24), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM126A RNA expression–survival associations across cancer types. High TMEM126A expression shows unfavorable associations in KICH, LIHC, UVM, ACC, HNSC and PAAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for TMEM126A RNA expression.
This table summarizes TMEM126A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TMEM126A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM126A shows higher tumor expression in KIRC, LIHC, CHOL, LUAD, STAD and COAD. The KIRC box plot shows higher TMEM126A RNA expression in tumor versus normal tissue (log2 FC = +0.603, t-test p < 0.001).
This table shows molecular features associated with TMEM126A in patient tissues and cancer cell lines. In patient samples, TMEM126A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM126A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
